We wanted to make the LMSR UK community aware of the Sophie Fitzpatrick Charitable Foundation for Rare Cancers, which provides financial support to eligible people living with rare cancers who are experiencing financial hardship.

The Foundation explains:

“The Sophie Fitzpatrick Charitable Foundation for Rare Cancers was set up to help ease the financial burden faced by people living with rare cancers, at what is often an extremely difficult time. We understand that a diagnosis can bring not only health challenges, but also significant financial pressure, particularly when treatment involves repeated journeys, time away from work and additional living costs.

We are here to offer practical support to those who have been diagnosed with a rare cancer, are experiencing financial hardship and are in receipt of a relevant benefit, such as PIP, ESA, Universal Credit or DLA. Our grants can help with the cost of transport, travel, sustenance and hotel accommodation, helping to ease some of the burden during what is often an overwhelming and deeply difficult time.”

If you are living with leiomyosarcoma and think you may be eligible for support, you can contact the Sophie Fitzpatrick Charitable Foundation for Rare Cancers at info@sfcfrc.com to discuss whether a grant may be available.

You can also find out more about the Foundation and its work on the Sophie Fitzpatrick Charitable Foundation for Rare Cancers website. 

Please note that grants are provided independently by the Sophie Fitzpatrick Charitable Foundation for Rare Cancers and are subject to their eligibility criteria and the discretion of their Trustees.

The post Financial Support for People Living with Rare Cancers appeared first on Leiomyosarcoma Research UK.

“Can I already access genomic testing on the NHS?”

The answer is yes – in many situations, genomic testing is already available for eligible NHS patients, including some people diagnosed with rare cancers such as Leiomyosarcoma.

What is genomic testing?

Every cancer develops because of changes, known as mutations or alterations, within a person’s DNA.

Genomic testing looks at these changes to build a clearer picture of the cancer. Rather than simply identifying where a tumour is in the body, genomic testing can help doctors understand the biology of the cancer itself.

This information may help clinicians:

• Confirm a diagnosis

• Identify genetic changes driving the cancer

• Inform treatment decisions

• Determine whether targeted therapies or clinical trials may be appropriate

• Improve understanding of rare cancers through ongoing research

Not every test looks at the whole genome. Depending on the clinical situation, testing may examine a single gene, a panel of genes or, in some cases, the entire genome.

Isn’t this something new?

The recent BBC coverage has focused on the Government’s longer-term ambition to expand genomic medicine across the NHS.

However, genomic testing itself is not new.

Since 2018, NHS England’s Genomic Medicine Service has been offering genomic testing for patients who meet specific clinical criteria. Today, specialist teams across England can request a range of genomic tests through the National Genomic Test Directory, including whole genome sequencing for certain rare diseases and cancers.

The latest announcements are about expanding and developing these services further, not starting from scratch.

What does this mean for people with Leiomyosarcoma?

Leiomyosarcoma is a rare and complex cancer.

Because it is uncommon, every opportunity to learn more about the disease is incredibly valuable.

Depending on an individual’s circumstances, genomic testing may already form part of their diagnostic or treatment pathway, particularly if they are being treated at a specialist sarcoma centre.

The results may help clinicians better understand the tumour and, in some cases, identify treatments or clinical trials that may be suitable. Not every patient will benefit directly from genomic testing today, and it does not yet provide all the answers. However, every test also contributes to improving scientific understanding of Leiomyosarcoma and other rare cancers.

Can I ask about genomic testing?

Absolutely.

If you have been diagnosed with Leiomyosarcoma and are unsure whether genomic testing has been considered, it is entirely reasonable to ask your specialist team.

Questions you might ask include:

• Has my tumour undergone genomic testing?

• Would genomic testing be appropriate in my case?

• Am I eligible under the NHS Genomic Medicine Service?

• Could genomic testing influence my treatment options?

• Are there any clinical trials that might be suitable?

Your healthcare team will be able to explain whether genomic testing is appropriate for your individual circumstances.

Looking ahead

The increased focus on genomic medicine is encouraging news for everyone affected by rare cancers.

As knowledge grows and technology advances, genomic testing has the potential to improve diagnosis, personalise treatment and accelerate research into diseases such as Leiomyosarcoma.

At Leiomyosarcoma Research UK, we welcome the continued investment in genomic medicine and hope it leads to greater opportunities for people living with this rare cancer.

Research, collaboration and earlier diagnosis all play an important role in improving outcomes, and genomics is becoming an increasingly important part of that journey.

If you would like to learn more about Leiomyosarcoma Research UK and our work supporting research, awareness and patients across the UK, please explore the rest of our website.

The post Genomic testing is making headlines – but what does it mean for people with Leiomyosarcoma? appeared first on Leiomyosarcoma Research UK.

Key Provisions of the Act

• Research Leadership: Appoints a named individual responsible for overseeing research delivery for rare cancer treatments.
• Orphan Drug Review: Places a duty on the government to review orphan drug regulations specifically for rare cancers.
• Clinical Trial Access: Ensures patients can be more easily contacted about relevant trials to improve participation and data quality.

The post Rare Cancer Bill passes into law appeared first on Leiomyosarcoma Research UK.

Read the full story at Northwestern Medicine.

The post Promising results from early stage trial appeared first on Leiomyosarcoma Research UK.